Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

Y. N.Vashisht Gopal, Helen Rizos, Guo Chen, Wanleng Deng, Dennie T. Frederick, Zachary A. Cooper, Richard A. Scolyer, Gulietta Pupo, Kakajan Komurov, Vasudha Sehgal, Jiexin Zhang, Lalit Patel, Cristiano G. Pereira, Bradley M. Broom, Gordon Mills, Prahlad Ram, Paul D. Smith, Jennifer A. Wargo, Georgina V. Long, Michael A. Davies

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Metabolic heterogeneity is a key factor in cancer pathogenesis. We found that a subset of BRAF- and NRAS-mutant human melanomas resistant to the MEK inhibitor selumetinib displayed increased oxidative phosphorylation (OxPhos) mediated by the transcriptional coactivator PGC1α. Notably, all selumetinib-resistant cells with elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055,whereas this combinationwas ineffective in resistant cell lines with lowOxPhos. In both BRAF- and NRAS -mutant melanoma cells, MEK inhibition increased MITF expression, which in turn elevated levels of PGC1α. In contrast, mTORC1/2 inhibition triggered cytoplasmic localization of MITF, decreasing PGC1α expression and inhibiting OxPhos. Analysis of tumor biopsies from patients with BRAF-mutant melanoma progressing on BRAF inhibitor ± MEK inhibitor revealed that PGC1α levels were elevated in approximately half of the resistant tumors. Overall, our findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.

Original languageEnglish (US)
Pages (from-to)7037-7047
Number of pages11
JournalCancer Research
Volume74
Issue number23
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Oxidative Phosphorylation
Melanoma
Mitogen-Activated Protein Kinase Kinases
Neoplasms
mechanistic target of rapamycin complex 1
Phenotype
Biopsy
Cell Line
AZD 6244

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gopal, Y. N. V., Rizos, H., Chen, G., Deng, W., Frederick, D. T., Cooper, Z. A., ... Davies, M. A. (2014). Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Research, 74(23), 7037-7047. https://doi.org/10.1158/0008-5472.CAN-14-1392

Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. / Gopal, Y. N.Vashisht; Rizos, Helen; Chen, Guo; Deng, Wanleng; Frederick, Dennie T.; Cooper, Zachary A.; Scolyer, Richard A.; Pupo, Gulietta; Komurov, Kakajan; Sehgal, Vasudha; Zhang, Jiexin; Patel, Lalit; Pereira, Cristiano G.; Broom, Bradley M.; Mills, Gordon; Ram, Prahlad; Smith, Paul D.; Wargo, Jennifer A.; Long, Georgina V.; Davies, Michael A.

In: Cancer Research, Vol. 74, No. 23, 01.12.2014, p. 7037-7047.

Research output: Contribution to journalArticle

Gopal, YNV, Rizos, H, Chen, G, Deng, W, Frederick, DT, Cooper, ZA, Scolyer, RA, Pupo, G, Komurov, K, Sehgal, V, Zhang, J, Patel, L, Pereira, CG, Broom, BM, Mills, G, Ram, P, Smith, PD, Wargo, JA, Long, GV & Davies, MA 2014, 'Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma', Cancer Research, vol. 74, no. 23, pp. 7037-7047. https://doi.org/10.1158/0008-5472.CAN-14-1392
Gopal, Y. N.Vashisht ; Rizos, Helen ; Chen, Guo ; Deng, Wanleng ; Frederick, Dennie T. ; Cooper, Zachary A. ; Scolyer, Richard A. ; Pupo, Gulietta ; Komurov, Kakajan ; Sehgal, Vasudha ; Zhang, Jiexin ; Patel, Lalit ; Pereira, Cristiano G. ; Broom, Bradley M. ; Mills, Gordon ; Ram, Prahlad ; Smith, Paul D. ; Wargo, Jennifer A. ; Long, Georgina V. ; Davies, Michael A. / Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. In: Cancer Research. 2014 ; Vol. 74, No. 23. pp. 7037-7047.
@article{5c4bdd3244824615b81286ae376f8e54,
title = "Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma",
abstract = "Metabolic heterogeneity is a key factor in cancer pathogenesis. We found that a subset of BRAF- and NRAS-mutant human melanomas resistant to the MEK inhibitor selumetinib displayed increased oxidative phosphorylation (OxPhos) mediated by the transcriptional coactivator PGC1α. Notably, all selumetinib-resistant cells with elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055,whereas this combinationwas ineffective in resistant cell lines with lowOxPhos. In both BRAF- and NRAS -mutant melanoma cells, MEK inhibition increased MITF expression, which in turn elevated levels of PGC1α. In contrast, mTORC1/2 inhibition triggered cytoplasmic localization of MITF, decreasing PGC1α expression and inhibiting OxPhos. Analysis of tumor biopsies from patients with BRAF-mutant melanoma progressing on BRAF inhibitor ± MEK inhibitor revealed that PGC1α levels were elevated in approximately half of the resistant tumors. Overall, our findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.",
author = "Gopal, {Y. N.Vashisht} and Helen Rizos and Guo Chen and Wanleng Deng and Frederick, {Dennie T.} and Cooper, {Zachary A.} and Scolyer, {Richard A.} and Gulietta Pupo and Kakajan Komurov and Vasudha Sehgal and Jiexin Zhang and Lalit Patel and Pereira, {Cristiano G.} and Broom, {Bradley M.} and Gordon Mills and Prahlad Ram and Smith, {Paul D.} and Wargo, {Jennifer A.} and Long, {Georgina V.} and Davies, {Michael A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-14-1392",
language = "English (US)",
volume = "74",
pages = "7037--7047",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma

AU - Gopal, Y. N.Vashisht

AU - Rizos, Helen

AU - Chen, Guo

AU - Deng, Wanleng

AU - Frederick, Dennie T.

AU - Cooper, Zachary A.

AU - Scolyer, Richard A.

AU - Pupo, Gulietta

AU - Komurov, Kakajan

AU - Sehgal, Vasudha

AU - Zhang, Jiexin

AU - Patel, Lalit

AU - Pereira, Cristiano G.

AU - Broom, Bradley M.

AU - Mills, Gordon

AU - Ram, Prahlad

AU - Smith, Paul D.

AU - Wargo, Jennifer A.

AU - Long, Georgina V.

AU - Davies, Michael A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Metabolic heterogeneity is a key factor in cancer pathogenesis. We found that a subset of BRAF- and NRAS-mutant human melanomas resistant to the MEK inhibitor selumetinib displayed increased oxidative phosphorylation (OxPhos) mediated by the transcriptional coactivator PGC1α. Notably, all selumetinib-resistant cells with elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055,whereas this combinationwas ineffective in resistant cell lines with lowOxPhos. In both BRAF- and NRAS -mutant melanoma cells, MEK inhibition increased MITF expression, which in turn elevated levels of PGC1α. In contrast, mTORC1/2 inhibition triggered cytoplasmic localization of MITF, decreasing PGC1α expression and inhibiting OxPhos. Analysis of tumor biopsies from patients with BRAF-mutant melanoma progressing on BRAF inhibitor ± MEK inhibitor revealed that PGC1α levels were elevated in approximately half of the resistant tumors. Overall, our findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.

AB - Metabolic heterogeneity is a key factor in cancer pathogenesis. We found that a subset of BRAF- and NRAS-mutant human melanomas resistant to the MEK inhibitor selumetinib displayed increased oxidative phosphorylation (OxPhos) mediated by the transcriptional coactivator PGC1α. Notably, all selumetinib-resistant cells with elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055,whereas this combinationwas ineffective in resistant cell lines with lowOxPhos. In both BRAF- and NRAS -mutant melanoma cells, MEK inhibition increased MITF expression, which in turn elevated levels of PGC1α. In contrast, mTORC1/2 inhibition triggered cytoplasmic localization of MITF, decreasing PGC1α expression and inhibiting OxPhos. Analysis of tumor biopsies from patients with BRAF-mutant melanoma progressing on BRAF inhibitor ± MEK inhibitor revealed that PGC1α levels were elevated in approximately half of the resistant tumors. Overall, our findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.

UR - http://www.scopus.com/inward/record.url?scp=84918582539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918582539&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1392

DO - 10.1158/0008-5472.CAN-14-1392

M3 - Article

C2 - 25297634

AN - SCOPUS:84918582539

VL - 74

SP - 7037

EP - 7047

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -